immunome - Robuta Search

https://www.businesswire.com/news/home/20211201005348/en/Immunome-Expects-IMM-BCP-01-Antibody-Cocktail-To-Neutralize-the-SARS-CoV-2-Omicron-Variant Immunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron Variant Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody the... https://investingnews.com/immunome-to-present-at-2nd-annual-guggenheim-healthcare-innovation-conference/ Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference | INN Oct 31, 2025 - Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that... 2nd annual healthcare innovation immunome present https://www.benzinga.com/quote/IMNM/news Latest Immunome Stock News | NASDAQ:IMNM | Benzinga Get the latest news on Immunome stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on IMNM performance stock news latest immunome nasdaq imnm https://www.longdom.org/conference-abstracts/posters-accepted-abstracts/immunology-congress-2018-proceedings-posters-accepted-abstracts-756.html Conference Proceedings | Posters & Accepted Abstracts | Immunome Research Longdom Publishing SL is one of the leading international open access journals publishers, covering clinical, medical, and technology-oriented subjects conference proceedings posters accepted abstracts immunome research https://www.biospace.com/immunome-appoints-sandra-m-swain-to-board-of-directors Immunome Appoints Sandra M. Swain to Board of Directors - BioSpace Jul 17, 2024 - Immunome, Inc., a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced the appointment of Sandra... sandra m swain board of directors immunome appoints https://www.businesswire.com/news/home/20230106005084/en/AbbVie-and-Immunome-Announce-Strategic-Collaboration-to-Discover-Multiple-Novel-Oncology-Targets AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets AbbVie (NYSE: ABBV) and Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to discover ... strategic collaboration https://investingnews.com/immunome-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference/ Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference | INN Sep 11, 2025 - Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that... https://immunaid.fr/ IMMUNAID Immunome project consortium for AutoInflammatory Disorders project consortium immunome autoinflammatory disorders https://www.fhi.no/nva-prosjekter/avsluttet/eximious---mapping-exposure-induced-immune-effects-connecting-the-exposome-/ EXIMIOUS - Mapping Exposure-Induced Immune Effects: Connecting the Exposome and the Immunome - FHI We will build a multifaceted toolbox to help assess the impact of the exposome on the immune system at the level of individuals and populations. https://investingnews.com/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors/ Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with... Dec 14, 2025 - Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ET Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class... https://www.businesswire.com/news/home/20210330005204/en/Immunome-Appoints-Dr.-Dennis-Giesing-as-Chief-Development-Officer Immunome Appoints Dr. Dennis Giesing as Chief Development Officer Immunome appoints Dennis Giesing, Ph.D. to the role of Chief Development Officer dr dennis immunome appoints giesing chief https://investingnews.com/immunome-presents-preclinical-data-showing-proprietary-top1i-adc-payload-hc74-overcomes-multiple-mechanisms-of-adc-resistance/ Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple... Oct 23, 2025 - Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented... https://investingnews.com/immunome-announces-positive-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors/ Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients... https://www.fxempire.com/forecasts/article/immunome-imnm-price-forecast-breakout-points-to-higher-highs-ahead-1591674 Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead | FXEmpire Immunome stock shows renewed strength after a pennant breakout, signaling a potential continuation of its recovery trend with upside momentum building toward... price forecast immunome imnm breakout https://www.businesswire.com/news/home/20210323005331/en/Immunome-Advances-Its-Proprietary-Antibody-Against-IL-38-a-Novel-Innate-Immune-Checkpoint-into-IND-enabling-Studies Immunome Advances Its Proprietary Antibody Against IL-38, a Novel Innate Immune Checkpoint, into... Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibo... https://www.businesswire.com/news/home/20210325005954/en/Immunome-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results-Provides-Corporate-Update Immunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-c... https://www.biospace.com/press-releases/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-july-3-2025 Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 3, 2025 - BioSpace https://www.macrotrends.net/stocks/charts/IMNM/immunome/quick-ratio Immunome Quick Ratio 2019-2026 | IMNM | MacroTrends Historical quick ratio values for Immunome (IMNM) over the last 10 years. quick ratio immunome 2019 2026 imnm https://www.longdom.org/special-issues/immunome-research-in-the-context-of-covid19-1700.html Immunome Research in the context of COVID-19 Immunome Research in the context of COVID-19, Immunome Research immunome research in the context covid 19 https://www.macrotrends.net/stocks/charts/IMNM/immunome/price-fcf Immunome Price to Free Cash Flow Ratio 2019-2026 | IMNM | MacroTrends Historical price to free cash flow ratio values for Immunome (IMNM) since 2019. free cash flow immunome price